High cost of dialysis slows APAC's kidney disease market

The market is dominated by the diagnosis segment.

The high cost of dialysis treatment in Asia-Pacific is slowing the growth of the kidney disease market in the region, which is tipped to reach $37.20b in 2027 from $21.9b in 2019, according to a report from Research and Markets.

The market is estimated to grow with a compound annual growth rate (CAGR) of 6.9% from 2020-2027, amidst a rising incidence of end-stage diseases and high development in government expenditure in the healthcare industry.

The diagnosis segment held the largest share of the market in 2019, and is anticipated to register the highest CAGR in the market during the period.

Chronic kidney disease can be diagnosed with blood and urine tests. The tests must be performed in conditions such as diabetes, high blood pressure, heart disease, and a family history of kidney failure.